Bio News
A model that predicts recurrence after immunotherapy in patients with high-risk melanoma based on gut microbiome “compatibility” achieved accuracy of up to 94%. The study, based on a global phase 3 clinical trial involving 674 patients, used a “matching” approach that compares patients’ gut microbiome characteristics with existing data rather than searching for specific beneficial bacteria. The findings provide a scientific basis for developing gut microbiome-based diagnostic tools to establish personalized treatment strategies for high-risk patients.
BIOBOOK TEAM
biobookmedia@biobook.co.krMerck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
RDA develops technology to produce anti-inflammatory exosomes for pets and files patent application
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
